Astragaloside Iv for Immune Function

Research suggests that astragaloside IV (AS-IV) exerts a broad range of immune-modulating effects, with studies pointing to its ability to restore regulatory T cell function, activate macrophages, suppress inflammatory signaling pathways, enhance antiviral innate immunity, and shift immune responses away from pro-inflammatory states in contexts ranging from autoimmune disease to cancer to viral infection. The available evidence comes predominantly from preclinical sources — including in vitro cell culture experiments, animal models of lupus, Parkinson's disease, lung cancer, colitis, and viral infections, as well as several narrative and systematic reviews — all of which trend in a supportive direction, with no studies in this collection reporting neutral or contradictory findings on immune outcomes. Studies indicate that multiple molecular pathways appear to be involved, including NF-κB, TLR4/NF-κB, cGAS-STING, and ITGB1/PTK2/p38, suggesting the compound acts through several mechanisms rather than a single target. However, the near-total absence of human clinical trials is a significant limitation, and the consistency of positive findings across preclinical studies should be interpreted cautiously, as effects observed in animals and cell cultures do not reliably translate to humans without further clinical investigation.